Suppr超能文献

多参数流式细胞术检测到微小残留阴性对 AL 淀粉样变性患者生存的影响。

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.

出版信息

Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23.

Abstract

Response assessment in light chain (AL) amyloidosis is challenging given the low level of circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a marrow aspirate was demonstrated to retain a prognostic significance in several recent studies. In this work, 82 AL patients who had MFC study at end of therapy were analysed based on whether clonal plasma cells were detected or not. Among patients who achieved deep response (i.e. very good partial response or complete response) to first-line therapy, lack of clonal marrow plasma cells as measured by MFC was associated with improved progression-free survival (PFS) compared to patients with residual clonal plasma cells (3-year PFS 88% vs. 46%,  = .003), particularly among patients who achieved a complete response (3-year PFS 100% vs. 33%,  = .001). Absence of clonal plasma cells by MFC compared with patients with detectable clonal plasma cells among deep responders was associated with lower level of involved light chain (involved free light chain (iFLC), median 1.1 vs. 1.7 mg/dL;  = .02) and higher frequency of renal response (100% vs. 68%;  = .005). Further studies are needed to determine if MFC should be incorporated into response criteria in AL amyloidosis.

摘要

由于通常观察到循环游离轻链水平较低,因此轻链 (AL) 淀粉样变性的反应评估具有挑战性。来自骨髓抽吸物的多参数流式细胞术 (MFC) 在最近的几项研究中被证明保留了预后意义。在这项工作中,根据是否检测到克隆浆细胞,对 82 名在治疗结束时进行 MFC 研究的 AL 患者进行了分析。在接受一线治疗达到深度缓解(即非常好的部分缓解或完全缓解)的患者中,与仍有克隆浆细胞的患者相比,MFC 测量的骨髓浆细胞缺乏克隆性与改善无进展生存期 (PFS) 相关(3 年 PFS 为 88% vs. 46%,=0.003),特别是在完全缓解的患者中(3 年 PFS 为 100% vs. 33%,=0.001)。与深度缓解者中可检测到克隆浆细胞的患者相比,MFC 检测到的克隆浆细胞缺乏与受累轻链水平较低(受累游离轻链 (iFLC),中位数为 1.1 与 1.7mg/dL;=0.02)和更高的肾脏反应频率(100%与 68%;=0.005)相关。需要进一步的研究来确定 MFC 是否应纳入 AL 淀粉样变性的反应标准。

相似文献

引用本文的文献

4
Bad players in AL amyloidosis in the current era of treatment.当前治疗时代的 AL 淀粉样变性中的不良预后因素。
Expert Rev Hematol. 2023 Jan;16(1):33-49. doi: 10.1080/17474086.2023.2166924. Epub 2023 Jan 12.
7
Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.轻链淀粉样变性:流行病学、分期和预后。
Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):27-35. doi: 10.14797/mdcvj.1070. eCollection 2022.
8
Biomarkers in AL Amyloidosis.AL 淀粉样变中的生物标志物。
Int J Mol Sci. 2021 Oct 9;22(20):10916. doi: 10.3390/ijms222010916.

本文引用的文献

1
Systemic immunoglobulin light chain amyloidosis.系统性免疫球蛋白轻链淀粉样变性。
Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3.
8
Multiple Myeloma Minimal Residual Disease.多发性骨髓瘤微小残留病
Cancer Treat Res. 2016;169:103-122. doi: 10.1007/978-3-319-40320-5_7.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验